[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

USA & Canada Cervical Cancer Diagnostic Market, Patients by Test Type (Pap Smear, HPV DNA), in North America

July 2018 | | ID: UF2E4CE7287EN
Renub Research

US$ 990.00

E-mail Delivery (PDF), Online Subscription, Hard Copy Mail Delivery, CD-ROM Mail Delivery, E-mail Delivery (Word)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Cervical cancer is the fourth most common cancer prevailing in women and the seventh in terms of overall cancer incidences. North America Cervical Cancer Screening Market is projected to reach US$ 100 Million by the year 2024. Cervical cancer affects the lower part of the uterus (womb). Cervical cancer generally occurs in women over 30 years. It is mostly caused by the Human papillomavirus (HPV) virus.

Increasing cervical cancer prevalence rate is one of the key factors that drive the cervical cancer screening market. Rapidly increasing female population, growing incidence of HPV infections and increasing awareness about cervical cancer screening programs is also expected to drive the cervical cancer screening market in the near future.

Renub Research report titled “USA & Canada Cervical Cancer Diagnostic Market, Patients by Test Type (Pap Smear, HPV DNA), in North America” provides a complete analysis of North America Cervical Cancer Screening Market. The report provides a complete analysis of North America Cervical Cancer Test Market, Screened Population & Mortality.

By Test Types – Pap smear Screening Tests is gaining popularity in North America

The report studies the market and population of the following cervical cancer screening tests: Pap smear Tests and HPV DNA Tests. Pap smear and HPV DNA tests are more popular with the developed countries such as United States.

By Country – United State has bright future in Cervical Cancer Screening Market in near future

The report studies the market/screened population of two big North America’s country (United State and Canada) which provides a complete country-wise analysis of North America Cervical Cancer Screening Market, Population and Mortality.

Cervical Cancer Diagnostic Market & Population
  • Pap Smear Tests Market
  • HPV DNA Tests Market
Cervical Cancer Mortality Population
  • United States
  • Canada
1. EXECUTIVE SUMMARY

2. NORTH AMERICA CERVICAL CANCER TEST (SCREENING) ANALYSIS

2.1 North America Cervical Cancer Test Population
  2.1.1 Pap Smear Test Population
  2.1.2 HPV DNA Test Population
2.2 North America Cervical Cancer Test (Screening) Market
  2.2.1 Pap Smear Test Market
  2.2.2 HPV DNA Test Market

3. MARKET & POPULATION SHARE – BY COUNTRIES

3.1 Population Share – By Countries
  3.1.1 Pap Smear Population
  3.1.2 HPV DNA Population
3.2 Market Share – By Countries
  3.2.1 Pap Smear Test Market
  3.2.2 HPV DNA Test Market

4. UNITED STATES – CERVICAL CANCER TEST ANALYSIS

4.1 Population – Cervical Cancer Test (Screening)
  4.1.1 Pap smear Test Population
  4.1.2 HPV DNA Test Population
4.2 United States Cervical Cancer Mortality
4.3 Market – Cervical Cancer Test (Screening)
  4.3.1 Pap Smear Test Market
  4.3.2 HPV DNA Test Market

5. CANADA – CERVICAL CANCER TEST ANALYSIS

5.1 Population – Cervical Cancer Test (Screening)
  5.1.1 Pap Smear Test Population
  5.1.2 HPV DNA Test Population
5.2 Canada Cervical Cancer Mortality
5.3 Market – Cervical Cancer Test (Screening)
  5.3.1 Pap Smear Test Market
  5.3.2 HPV DNA Test Market

6. GROWTH DRIVERS

6.1 High Prevalence of HPV Infected Patients
6.2 Worldwide Rising Incidence of Teenage Sexual Cases

7. CHALLENGES

7.1 Introduction of HPV Vaccination Programs Worldwide

LIST OF FIGURES:

Figure 2-1: North America – Cervical Cancer Test Population (Million), 2011 – 2017
Figure 2-2: North America – Forecast for Cervical Cancer Test Population (Million), 2018 – 2024
Figure 2-3: North America – Cervical Cancer Pap smear Test Population (Million), 2011 – 2017
Figure 2-4: North America – Forecast for Cervical Cancer Pap smear Test Population (Million), 2018 – 2024
Figure 2-5: North America – Cervical Cancer HPV DNA Test Population (Million), 2011 – 2017
Figure 2-6: North America – Forecast for Cervical Cancer HPV DNA Test Population (Million), 2018 – 2024
Figure 2-7: North America – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 2-8: North America – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 2-9: North America – Cervical Cancer Pap Smear Test Market (Million US$), 2011 – 2017
Figure 2-10: North America – Forecast for Cervical Cancer Pap Smear Test Market (Million US$), 2018 – 2024
Figure 2-11: North America – Cervical Cancer HPV DNA Test Market (Million US$), 2011 – 2017
Figure 2-12: North America – Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2018 – 2024
Figure 3-1: North America – Cervical Cancer Test Population Share (%), 2011 – 2017
Figure 3-2: North America – Forecast for Cervical Cancer Test Population Share (%), 2018 – 2024
Figure 3-3: North America – Cervical Cancer Pap smear Test Population Share (%), 2011 – 2017
Figure 3-4: North America – Forecast for Cervical Cancer Pap smear Test Population Share (%), 2018 – 2024
Figure 3-5: North America – Cervical Cancer HPV DNA Test Population Share (%), 2011 – 2017
Figure 3-6: North America – Forecast for Cervical Cancer HPV DNA Test Population Share (%), 2018 – 2024
Figure 3-7: North America – Cervical Cancer Test Market Share (%), 2011 – 2017
Figure 3-8: North America – Forecast for Cervical Cancer Test Market Share (%), 2018 – 2024
Figure 3-9: North America – Cervical Cancer Pap smear Test Market Share (%), 2011 – 2017
Figure 3-10: North America – Forecast for Cervical Cancer Pap smear Test Market Share (%), 2018 – 2024
Figure 3-11: North America – Cervical Cancer HPV DNA Test Market Share (%), 2011 – 2017
Figure 3-12: North America – Forecast for Cervical Cancer HPV DNA Test Market Share (%), 2018 – 2024
Figure 4-1: United States – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 4-2: United States – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 4-3: United States – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 4-4: United States – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 4-5: United States – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 4-6: United States – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
Figure 4-7: United States – Cervical Cancer Mortality (Number), 2011 – 2017
Figure 4-8: United States – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 4-9: United States – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 4-10: United States – Pap smear Test Market (Million US$), 2011 – 2017
Figure 4-11: United States – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 4-12: United States – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 4-13: United States – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024
Figure 5-1: Canada – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 5-2: Canada – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 5-3: Canada – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 5-4: Canada – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 5-5: Canada – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 5-6: Canada – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
Figure 5-7: Canada – Cervical Cancer Mortality (Number), 2011 – 2017
Figure 5-8: Canada – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 5-9: Canada – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 5-10: Canada – Pap Smear Test Market (Million US$), 2011 – 2017
Figure 5-11: Canada – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 5-12: Canada – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 5-13: Canada – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024

LIST OF TABLES:

Table 6 1: Worldwide – Prevalence of HPV 16/18 in Women with Normal Cervical Cytology (Percent), 2014 - 2015
Table 6 2: Worldwide – Prevalence (Percent) of Young Women (15–44 Years) who Have Sex before the Age of 15 Years, 1994 – 2006


More Publications